{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:40:30Z","timestamp":1768322430659,"version":"3.49.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contraceptionjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.contraception.2017.12.003","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T02:40:12Z","timestamp":1512960012000},"page":"191-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?"],"prefix":"10.1016","volume":"97","author":[{"given":"Chelsea B.","family":"Polis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L.","family":"Achilles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdenek","family":"Hel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet P.","family":"Hapgood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2017.12.003_bb0005","series-title":"Trends in contraceptive use worldwide 2015 (ST\/ESA\/SER.A\/349)","author":"United Nations","year":"2015"},{"key":"10.1016\/j.contraception.2017.12.003_bb0010","first-page":"587","article-title":"Rising popularity of injectable contraceptives in sub-Saharan Africa","volume":"25","author":"Adetunji","year":"2011","journal-title":"Afr Popul Stud"},{"key":"10.1016\/j.contraception.2017.12.003_bb0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(12)60478-4","article-title":"Maternal deaths averted by contraceptive use: an analysis of 172 countries","volume":"380","author":"Ahmed","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2017.12.003_bb0020","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/QAD.0000000000001228","article-title":"An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women","volume":"30","author":"Polis","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2017.12.003_bb0025","series-title":"Hormonal contraceptive eligibility for women at high risk of HIV. Guidance statement: Recommendations concerning the use of hormonal contraceptive methods by women at high risk of HIV","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.contraception.2017.12.003_bb0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.contraception.2004.06.011","article-title":"Contraceptive efficacy and safety of DMPA-SC","volume":"70","author":"Jain","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/17455057.2.2.191","article-title":"Subcutaneous versus intramuscular depot methoxyprogesterone acetate: a comparative review","volume":"2","author":"Simon","year":"2006","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.contraception.2017.12.003_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.contraception.2009.02.005","article-title":"Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density","volume":"80","author":"Kaunitz","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0045","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.contraception.2016.02.003","article-title":"The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg\/0.65mL): a systematic review","volume":"94","author":"Dragoman","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.contraception.2013.10.010","article-title":"Subcutaneous DMPA: a better lower dose approach","volume":"89","author":"Shelton","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.contraception.2014.02.010","article-title":"Sayana\u00ae press: can it be a \u201cgame changer\" for reducing unmet need for family planning?","volume":"89","author":"Spieler","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0060","series-title":"Advocacy pack for subcutaneous DMPA","author":"PATH","year":"2017"},{"key":"10.1016\/j.contraception.2017.12.003_bb0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.contraception.2014.01.022","article-title":"Observational study of the acceptability of Sayana\u00ae press among intramuscular DMPA users in Uganda and Senegal","volume":"89","author":"Burke","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.contraception.2013.11.008","article-title":"Preference for Sayana\u00ae press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial","volume":"89","author":"Polis","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0075","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.contraception.2014.01.009","article-title":"Provider acceptability of Sayana\u00ae press: results from community health workers and clinic-based providers in Uganda and Senegal","volume":"89","author":"Burke","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0080","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.contraception.2013.12.010","article-title":"Perceptions of home and self-injection of Sayana\u00ae Press in Ethiopia: a qualitative study","volume":"89","author":"Keith","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.contraception.2016.06.006","article-title":"Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States","volume":"94","author":"Upadhyay","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.contraception.2011.09.015","article-title":"Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability","volume":"85","author":"Prabhakaran","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0095","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.contraception.2011.10.002","article-title":"Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception","volume":"85","author":"Cameron","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0100","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.contraception.2016.05.006","article-title":"The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study","volume":"94","author":"Kaplan","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0105","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.contraception.2014.01.026","article-title":"Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate","volume":"89","author":"Beasley","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.contraception.2012.11.019","article-title":"Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women","volume":"88","author":"Williams","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0115","author":"FHI360"},{"issue":"Suppl. 1","key":"10.1016\/j.contraception.2017.12.003_bb0120","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/QAD.0000000000000036","article-title":"Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches","volume":"27","author":"Polis","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2017.12.003_bb0125","doi-asserted-by":"crossref","first-page":"e1001778","DOI":"10.1371\/journal.pmed.1001778","article-title":"Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis","volume":"12","author":"Morrison","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.contraception.2017.12.003_bb0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(14)71052-7","article-title":"Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies","volume":"15","author":"Ralph","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.contraception.2017.12.003_bb0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1210\/er.2009-0018","article-title":"Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection","volume":"31","author":"Hel","year":"2010","journal-title":"Endocr Rev"},{"key":"10.1016\/j.contraception.2017.12.003_bb0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/aji.12209","article-title":"Research gaps in defining the biological link between HIV risk and hormonal contraception","volume":"72","author":"Murphy","year":"2014","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0145","unstructured":"U.S. Food and Drug Administration. Depo-SubQ Provera 104 (Medroxyprogesterone Acetate) Injectable Suspension New Drug Application No.: 021583. Center for Drug Evaluation and Research Clinical Pharmacology and Biopharmaceutics Review; 2014."},{"key":"10.1016\/j.contraception.2017.12.003_bb0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.contraception.2016.03.003","article-title":"Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial","volume":"94","author":"Nanda","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.contraception.2004.01.011","article-title":"Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera","volume":"70","author":"Jain","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0160","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2004.11.013","article-title":"Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg\/0.65 mL) contraceptive formulation in Asian women","volume":"26","author":"Toh","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.contraception.2017.12.003_bb0165","first-page":"31","article-title":"Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm","author":"Halpern","year":"2014"},{"key":"10.1016\/j.contraception.2017.12.003_bb0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jcem-44-1-32","article-title":"Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA","volume":"44","author":"Ortiz","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2017.12.003_bb0175","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/acta.0.0990339","article-title":"Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent","volume":"99","author":"Jeppsson","year":"1982","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0015-0282(16)44895-8","article-title":"A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate","volume":"34","author":"Fotherby","year":"1980","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2017.12.003_bb0185","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.fertnstert.2007.07.1348","article-title":"Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy","volume":"90","author":"Nanda","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2017.12.003_bb0190","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.contraception.2014.01.017","article-title":"A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females","volume":"89","author":"Bonny","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0010-7824(74)90130-9","article-title":"Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera)","volume":"10","author":"Kirton","year":"1974","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0200","first-page":"57","article-title":"Injected long--acting medroxyprogesterone acetate. Effect on human lactation and concentrations in milk","volume":"60","author":"Koetsawang","year":"1977","journal-title":"J Med Assoc Thail"},{"key":"10.1016\/j.contraception.2017.12.003_bb0205","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0022-4731(78)90631-3","article-title":"A radioimmunoassay for serum medroxyprogesterone acetate","volume":"9","author":"Shrimanker","year":"1978","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.contraception.2017.12.003_bb0210","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0010-7824(80)90105-5","article-title":"Pharmacokinetic study of different doses of Depo Provera","volume":"22","author":"Fotherby","year":"1980","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0010-7824(82)90171-8","article-title":"Metabolism of injectable formulations of contraceptive steroids in obese and thin women","volume":"26","author":"Fotherby","year":"1982","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0220","first-page":"157","article-title":"Concentration changes of medroxyprogesterone acetate in serum and milk in lactating woman who used Depo Geston\u00ae","volume":"15","author":"Fang","year":"2004","journal-title":"J Reprod Contracept"},{"key":"10.1016\/j.contraception.2017.12.003_bb0225","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0010-7824(96)00170-9","article-title":"Pharmacodynamic effects of depot-medroxyprogesterone acetate (DMPA) administered to lactating women on their male infants","volume":"54","author":"Virutamasen","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0230","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0010-7824(76)80060-1","article-title":"Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of Depo-ProveraR to women","volume":"14","author":"Jeppsson","year":"1976","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0235","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0022-4731(81)90015-7","article-title":"Medroxyprogesterone acetate in human serum","volume":"14","author":"Mathrubutham","year":"1981","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.contraception.2017.12.003_bb0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.contraception.2003.09.005","article-title":"Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval","volume":"69","author":"Smit","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2017.12.003_bb0245","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0015-0282(16)48016-7","article-title":"Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses","volume":"42","author":"Bassol","year":"1984","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2017.12.003_bb0250","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.clpt.6100040","article-title":"Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions","volume":"81","author":"Cohn","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2017.12.003_bb0255","first-page":"381","article-title":"Pharmacokinetics of depot medroxyprogesterone acetate contraception","volume":"41","author":"Mishell","year":"1996","journal-title":"J Reprod Med"},{"key":"10.1016\/j.contraception.2017.12.003_bb0260","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.steroids.2011.03.001","article-title":"Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception","volume":"76","author":"Africander","year":"2011","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2017.12.003_bb0265","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr Rev"},{"key":"10.1016\/j.contraception.2017.12.003_bb0270","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.mce.2008.10.008","article-title":"Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction","volume":"299","author":"Ronacher","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0275","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/infdis\/jiv233","article-title":"CCR5 expression levels in HIV-uninfected women receiving hormonal contraception","volume":"212","author":"Sciaranghella","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.contraception.2017.12.003_bb0280","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(15)00429-6","article-title":"Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study","volume":"16","author":"Byrne","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.contraception.2017.12.003_bb0285","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/QAI.0000000000000531","article-title":"Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract","volume":"68","author":"Michel","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2017.12.003_bb0290","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/en.2012-1850","article-title":"Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms","volume":"154","author":"Huijbregts","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.contraception.2017.12.003_bb0295","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/mi.2016.22","article-title":"Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection","volume":"9","author":"Quispe Calla","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jri.2015.03.007","article-title":"Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive","volume":"110","author":"Ngcapu","year":"2015","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0305","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/aji.12415","article-title":"Injectable progestin-only contraception is associated with increased levels of pro-inflammatory cytokines in the female genital tract","volume":"74","author":"Deese","year":"2015","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0310","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QAI.0000000000000103","article-title":"Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion","volume":"66","author":"Morrison","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2017.12.003_bb0315","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-15","article-title":"The contribution of cervicovaginal infections to the immunomodulatory effects of hormonal contraception","volume":"6","author":"Fichorova","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.contraception.2017.12.003_bb0320","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1177\/1933719114565035","article-title":"Progestin-containing contraceptives alter expression of host defense-related genes of the endometrium and cervix","volume":"22","author":"Goldfien","year":"2015","journal-title":"Reprod Sci"},{"key":"10.1016\/j.contraception.2017.12.003_bb0325","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.fertnstert.2007.01.046","article-title":"Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users","volume":"90","author":"Li","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2017.12.003_bb0330","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0015-0282(02)04930-0","article-title":"Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium","volume":"79","author":"Fleming","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2017.12.003_bb0335","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/QAI.0000000000000975","article-title":"A depot medroxyprogesterone acetate dose that models human use and its effect on vaginal SHIV acquisition risk","volume":"72","author":"Butler","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2017.12.003_bb0340","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1128\/IAI.01189-12","article-title":"The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with mycobacterium tuberculosis","volume":"81","author":"Kleynhans","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.contraception.2017.12.003_bb0345","doi-asserted-by":"crossref","first-page":"37723","DOI":"10.1038\/srep37723","article-title":"Dendritic cell function and pathogen-specific T cell immunity are inhibited in mice administered levonorgestrel prior to intranasal chlamydia trachomatis infection","volume":"6","author":"Quispe Calla","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.contraception.2017.12.003_bb0350","doi-asserted-by":"crossref","first-page":"9845","DOI":"10.1128\/JVI.77.18.9845-9851.2003","article-title":"Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2","volume":"77","author":"Gillgrass","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0355","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.4049\/jimmunol.1103054","article-title":"Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection","volume":"189","author":"Vicetti Miguel","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0360","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/QAD.0000000000000681","article-title":"Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro","volume":"29","author":"Sampah","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2017.12.003_bb0365","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/humrep\/dev035","article-title":"Medroxyprogesterone acetate impairs human dendritic cell activation and function","volume":"30","author":"Quispe Calla","year":"2015","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2017.12.003_bb0370","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/infdis\/jiu832","article-title":"Medroxyprogesterone acetate regulates HIV-1 uptake and transcytosis but not replication in primary genital epithelial cells, resulting in enhanced T-cell infection","volume":"211","author":"Ferreira","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.contraception.2017.12.003_bb0375","doi-asserted-by":"crossref","first-page":"e96497","DOI":"10.1371\/journal.pone.0096497","article-title":"The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor","volume":"9","author":"Govender","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2017.12.003_bb0380","doi-asserted-by":"crossref","first-page":"31136","DOI":"10.1074\/jbc.M114.587311","article-title":"Medroxyprogesterone acetate differentially regulates interleukin (IL)-12 and IL-10 in a human ectocervical epithelial cell line in a glucocorticoid receptor (GR)-dependent manner","volume":"289","author":"Louw-du Toit","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.contraception.2017.12.003_bb0385","doi-asserted-by":"crossref","first-page":"e62895","DOI":"10.1371\/journal.pone.0062895","article-title":"The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor","volume":"8","author":"Tomasicchio","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2017.12.003_bb0390","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2005.07.001","article-title":"Synthetic progestins used in HRT have different glucocorticoid agonist properties","volume":"242","author":"Koubovec","year":"2005","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0395","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mce.2004.03.006","article-title":"Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells","volume":"221","author":"Koubovec","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0400","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bbrc.2013.02.086","article-title":"Investigating the anti-mineralocorticoid properties of synthetic progestins used in hormone therapy","volume":"433","author":"Africander","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.contraception.2017.12.003_bb0405","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jsbmb.2014.05.007","article-title":"A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A)","volume":"143","author":"Africander","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0410","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/mend.15.2.0596","article-title":"New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties","volume":"15","author":"Giannoukos","year":"2001","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.contraception.2017.12.003_bb0415","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.steroids.2007.10.003","article-title":"Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile","author":"Sasagawa","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2017.12.003_bb0420","first-page":"e24639","article-title":"Medroxyprogesterone acetate alters mycobacterium bovis BCG-induced cytokine production in peripheral blood mononuclear cells of contraceptive users","author":"Kleynhans","year":"2011"},{"key":"10.1016\/j.contraception.2017.12.003_bb0425","doi-asserted-by":"crossref","first-page":"E181","DOI":"10.1073\/pnas.1617115114","article-title":"Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy","volume":"114","author":"Engler","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.contraception.2017.12.003_bb0430","author":"Motulsky"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782417305292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782417305292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T16:29:27Z","timestamp":1570465767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782417305292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0010782417305292"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2017.12.003","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2017.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}